Communiqués

06/07 2cureX AB accelerates reintegration of operating business into the listed company AQ
25/06 2cureX : The Directed Issue announced 22 April 2026 will be registered at Bolagsverket under the authorization granted by the Annual General Meeting held on 25 June 2026. PU
25/06 Communiqué from the Annual General Meeting on Thursday 25 June 2026 in 2cureX AB AQ
28/05 THIS PRESS RELEASE IS AN ENGLISH TRANSLATION OF THE LEGALLY BINDING SWEDISH PRESS RELEASE: “PUBLICERING AV ÅRSREDOVISNINGEN FÖR 2CUREX AB (publ)”. AQ
25/05 Notice of annual general meeting in 2cureX AB AQ
20/05 2cureX AB Expands Functional Precision Medicine Infrastructure Through Strategic Collaboration with StoreMyTumor AQ
19/05 2cureX AB’s Executive Management is pleased to invite shareholders and investors to a live webcast and business update on 20 May at 7pm CET. AQ
22/04 2cureX AB completes oversubscribed directed issue AQ
26/02 2cureX AB (publ) publishes Interim Report for the Second Half of 2025 AQ
29/08/25 CEO Nathaniel Hutley presents a strategic update on 2cureX’s new Website Blog. AQ
21/08/25 2cureX AB (“2cureX”) hereby publishes the interim report for the first half year of 2025. AQ
11/07/25 Improved communication from 2cureX AB AQ
02/07/25 Correction: CEO Nathaniel Hutley presents latest news from 2cureX on July 2nd 2025. AQ
01/07/25 2cureX AB is in the process of securing a strategic collaboration with PreComb Therapeutics AG. AQ
13/06/25 CEO Nathaniel Hutley presents latest news from 2cureX on July 2nd 2025. AQ
30/05/25 NOTICE OF ANNUAL GENERAL MEETING OF 2CUREX AB (publ). AQ
29/05/25 RELEASE OF THE 2CUREX AB (PUBL) ANNUAL REPORT AQ
22/05/25 2cureX appoints Mangold Fondkommission AB as new Certified Adviser AQ
20/05/25 2cureX Conducts First Direct-to-Patient IndiTreat® Test Under “Operation Twin Code” Strategy AQ
15/05/25 2cureX AB (2CUREX) Launches “Operation Twin Code” with New Investors, Leadership Transition, and Global Roadmap AQ
14/04/25 EARLY NOTICE OF ANNUAL GENERAL MEETING OF 2CUREX AB (publ) AQ
27/02/25 2cureX publishes interim report for the second half year of 2024 AQ
18/12/24 BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN 2CUREX AB (PUBL) AQ
16/12/24 2cureX AB Announces the Appointment of Dan Honeywell as CEO, Ushering in a New Era of commercial expansion of breakthrough precision oncology products AQ
29/11/24 NOTICE OF EXTRA GENERAL MEETING IN 2CUREX AB AQ
Aucun résultat pour cette recherche